HC Wainwright reaffirmed their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO – Free Report) in a research note ...

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) have been assigned a consensus recommendation of ...

Analysts have recently evaluated Sangamo Therapeutics and provided 12-month price targets. The average target is $8.09, accompanied by a high estimate of $10.00 and a low estimate of $2.00. Surpassing ...

On Wednesday, Sangamo Therapeutics Inc (SGMO) stock saw a modest uptick, ending the day at $1.13 which represents no change from the prior close of of $1.13. The stock opened at $1.12 and touched a ...

In the last three months, 11 analysts have published ratings on Sangamo Therapeutics (NASDAQ:SGMO), offering a diverse range of perspectives from bullish to bearish. The table below provides a ...

Sangamo Therapeutics Inc (SGMO) stock saw a decline, ending the day at $1.16 which represents a decrease of $-0.03 or -2.52% from the prior close of $1.19. The stock opened at $1.21 and touched a low ...

Global Thalassemia Market Global Thalassemia Market Dublin, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The "Thalassemia Market by ...

Learn more about whether Biogen Inc. or Natera, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target ...